# EDGAR Filing Document

**Accession Number:** 0001673743
**File Stem:** 0001628280-26-030499
**Filing Date:** 2026-5
**Character Count:** 41475
**Document Hash:** c7e36d795e47c458778ca74e27af29be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-030499.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001628280-26-030499

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260505

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hinge Health, Inc.
- **CENTRAL INDEX KEY:** 0001673743
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 811884841
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42657
- **FILM NUMBER:** 26943026

**BUSINESS ADDRESS:**
- **STREET 1:** 455 MARKET STREET
- **STREET 2:** 7TH FLOOR
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105
- **BUSINESS PHONE:** 415-689-8429

**MAIL ADDRESS:**
- **STREET 1:** 455 MARKET STREET
- **STREET 2:** 7TH FLOOR
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105

?xml version='1.0' encoding='ASCII'? hnge-20260505

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

________________________________________________________

**FORM 8-K**

________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 5, 2026**

________________________________________________________

**Hinge Health, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42657** | **81-1884841** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| **455 Market Street, Suite 700** | | |
| **San Francisco, California** | | **94105** |
| **(Address of Principal Executive Offices)** | | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (415) 726-2206**

________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock, par value $0.00001 per share | HNGE | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 2.02. Results of Operations and Financial Condition.**

On May 5, 2026, Hinge Health, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026. In the press release, the Company also announced that it would hold a conference call to discuss these financial results on May 5, 2026 at 1:30 p.m. Pacific time (4:30 p.m. Eastern time).

The Company makes reference to non-GAAP financial information in the press release and on the conference call. A reconciliation of these non-GAAP financial measures to their nearest GAAP equivalents is provided in the press release.

The information in Item 2.02 of this Current Report on Form 8-K ("Form 8-K") and in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Form 8-K and in the accompanying Exhibit 99.1 attached hereto shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure.**

On May 5, 2026, the Company posted supplemental investor materials on the investor relations section of its website (ir.hingehealth.com). The Company uses its ir.hingehealth.com website as a means of disclosing material non-public information, announcing upcoming investor conferences and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's investor relations website in addition to the Company's SEC filings, press releases, public conference calls and webcasts.

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1\* | <u>[Press Release, dated May 5, 2026, issued by Hinge Health, Inc.](hnge-q1202655xex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

_______________________________________

\*Furnished herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | Hinge Health, Inc. |
| Date: | May 5, 2026 | By: | /s/ James Budge |
|  |  |  | &nbsp;&nbsp;&nbsp;&nbsp;James Budge, Chief Financial Officer |

---

## Exhibit 99.1

&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 99.1

**<u>Hinge Health reports record first quarter 2026 financial results</u>**

**San Francisco, California – May 5, 2026** – Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the first quarter ended March 31, 2026.

"We generated $182 million in revenue this quarter with 47% year-over-year growth, well ahead of expectations, driven by the strength of a platform that automates care delivery, improves member outcomes and lowers costs," said Daniel Perez, Co-Founder and CEO, Hinge Health. "Based on this momentum, we're raising our full-year revenue outlook by approximately $64 million at the midpoint to $801 million, while expanding non-GAAP operating margin to 26%. We also recently announced our Migraine Care Program, an important step in expanding our platform. We didn't build this company to stop at digital physical therapy; we built it to transform how healthcare is delivered at scale."

**First Quarter Financial Highlights:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Revenue** increased 47% year-over-year to $182.3 million compared to revenue of $123.8 million in Q1 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP and Non-GAAP gross margin** were 85% compared to 81% in Q1 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP income from operations** increased 144% to $32.1 million compared to GAAP income from operations of $13.1 million in Q1 2025. **Non-GAAP income from operations** increased 208% to $46.2 million compared to non-GAAP income from operations of $15.0 million in Q1 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP diluted net income per share** was $0.41. **Non-GAAP diluted net income per share** was $0.45.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net cash provided by operating activities** increased to $43.1 million compared to net cash provided by operating activities of $4.9 million in Q1 2025. **Free cash flow** increased to $41.6 million compared to free cash flow of $4.2 million in Q1 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash, cash equivalents, marketable securities and restricted cash** were $407.1 million as of March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Diluted weighted average share count** was 82.4 million, a decrease of 2.5% from the diluted weighted average share count of 84.5 million in Q4 2025.

**Company Highlights and Key Metrics as of March 31, 2026:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **LTM calculated billings** increased 52% year-over-year to $769.9 million, compared to $507.0 million as of March 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Number of clients** increased 23% year-over-year to 2,849 clients, compared to 2,311 clients as of March 31, 2025.

**Financial Outlook:**

We are providing the following guidance for our second quarter 2026 and full year 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Q2 2026:** We expect revenue to be between $194 million and $196 million, reflecting year-over-year growth of 40% at the midpoint. We expect non-GAAP income from operations to be between $47 million and $49 million, reflecting year-over-year growth of 84% and non-GAAP operating margin of 25% at the midpoint.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Full Year 2026:** We expect revenue to be between $798 million and $804 million, reflecting year-over-year growth of 36% at the midpoint. We expect non-GAAP income from operations to be between $205 million and $215 million, reflecting year-over-year growth of 76% and non-GAAP operating margin of 26% at the midpoint.

------

**Statement Regarding Use of Non-GAAP Financial Measures**

This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the "Non-GAAP Financial Measures" section below.

Moreover, we have not reconciled our non-GAAP income from operations guidance to GAAP income from operations because we do not and are not able to provide guidance for GAAP income from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as acquisition related expense, which are reconciling items between non-GAAP and GAAP income from operations. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income from operations.

**Hinge Health Earnings Webcast**

We will host a conference call and webcast for investors on May 5, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations. Following completion of the event, a webcast replay will also be available at ir.hingehealth.com for 12 months.

**About Hinge Health**

Hinge Health is focused on scaling and automating the delivery of health care. Leveraging an AI-powered care model, wearable devices and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain that improves member outcomes and experiences while reducing costs for clients. The company is headquartered in San Francisco, California.

**Available Information**

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including filings with the U.S. Securities and Exchange Commission ("SEC"), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.

**Forward-Looking Statements**

*This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," or "will," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the second quarter of 2026 and guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 3, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, when filed with the SEC. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.*

------

**HINGE HEALTH, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(unaudited)**

**(in thousands, except par value data)**

---

| | | |
|:---|:---|:---|
| | **March 31,** | **December 31,** |
| | **2026** | **2025** |
| Assets |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $186671 | $207995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term marketable securities | 129196 | 155867 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for credit losses of $5,957 and $6,092 as of March 31, 2026 and December 31, 2025, respectively | 114921 | 66061 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred commissions | 34507 | 31344 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 14167 | 15636 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 60592 | 57001 |
| Total current assets | 540054 | 533904 |
| Long-term marketable securities | 89769 | 113172 |
| Goodwill | 64096 | 64096 |
| Intangible assets, net | 2287 | 2512 |
| Property, equipment and software, net | 11350 | 10490 |
| Operating lease right-of-use assets | 5956 | 6861 |
| Other assets | 15259 | 13726 |
| Total assets | $728771 | $744761 |
| Liabilities, redeemable convertible preferred stock and stockholders' equity |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $69476 | $57331 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 4234 | 4223 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 340766 | 300855 |
| Total current liabilities | 414476 | 362409 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, noncurrent | 2735 | 3816 |
| Total liabilities | 417211 | 366225 |
| Redeemable convertible preferred stock: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redeemable convertible preferred stock; $0.00001 par value | 199874 | 199874 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A common stock, $0.00001 par value |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class B common stock, $0.00001 par value |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 1127902 | 1229678 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (348) | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1015868) | (1050996) |
| Total stockholders' equity | 111686 | 178662 |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity | $728771 | $744761 |

---

------

**HINGE HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(unaudited)**

**(in thousands, except per share data)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue | $182307 | $123825 |
| Cost of revenue | 28074 | 23592 |
| Gross profit | 154233 | 100233 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 30338 | 23499 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 68802 | 46716 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 23024 | 16881 |
| Total operating expenses | 122164 | 87096 |
| Income from operations | 32069 | 13137 |
| Other income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 3873 | 5000 |
| Net income before income taxes | 35942 | 18137 |
| Provision for income taxes | 814 | 998 |
| Net income | $35128 | $17139 |
| Adjustment to reflect deemed contribution<br> from Series D and Series E redeemable<br> convertible preferred stock extinguishment |  | 104174 |
| Undistributed earnings attributable to participating<br> securities | (1117) |  |
| Net income attributable to<br> common stockholders, basic | $34011 | $121313 |
| Net income attributable to<br> common stockholders, diluted | $34061 | $121313 |
| Net income attributable to common<br> stockholders per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.43 | $7.91 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.41 | $1.31 |
| Weighted average shares used in computing net<br> income per share attributable to common<br> stockholders: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 78619 | 15332 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 82394 | 92746 |

---

------

**HINGE HEALTH, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)**

**(in thousands)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Net income | $35128 | $17139 |
| &nbsp;&nbsp;&nbsp;&nbsp; Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization | 1173 | 1303 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stock-based compensation | 11692 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amortization of deferred commissions | 16205 | 9190 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accretion of discounts and amortization of premiums on marketable securities, net | 135 | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-cash operating lease expense | 905 | 845 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provision for credit losses |  | 886 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred income taxes |  | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other |  | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp; Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts receivable | (48860) | (34280) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred commissions | (20603) | (10630) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventory | 1470 | (1912) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepaid expenses and other current assets | (3590) | 8134 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other assets | (658) | (274) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable and accrued liabilities | 11246 | 15710 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating lease liabilities | (1070) | (941) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue | 39910 | (305) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 43083 | 4925 |
| Investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Purchase of property and equipment | (83) | (51) |
| &nbsp;&nbsp;&nbsp;&nbsp; Capitalized internal use software | (1447) | (706) |
| &nbsp;&nbsp;&nbsp;&nbsp; Purchases of marketable securities | (58956) | (90172) |
| &nbsp;&nbsp;&nbsp;&nbsp; Maturities of marketable securities | 108567 | 73598 |
| &nbsp;&nbsp;&nbsp;&nbsp; Acquisition of a business |  | (4000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 48081 | (21331) |
| Financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Proceeds from exercise of common stock options | 410 | 97 |
| &nbsp;&nbsp;&nbsp;&nbsp; Repurchase and retirement of common stock | (104966) |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Tax withholdings on settlement of restricted stock units and performance-based restricted stock units | (8292) |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Proceeds from repayment of non-recourse loans to employees |  | 4934 |
| &nbsp;&nbsp;&nbsp;&nbsp; Payments for deferred offering costs |  | (927) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) financing activities | (112848) | 4104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net decrease in cash, cash equivalents and restricted cash | (21684) | (12302) |
| Cash, cash equivalents, and restricted cash, beginning of period | 209796 | 302586 |
| Cash, cash equivalents, and restricted cash, end of period | $188112 | $290284 |
| Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets: |  |  |
| Cash and cash equivalents | $186671 | $288482 |
| Restricted cash | 1441 | 1802 |
| Total cash, cash equivalents, and restricted cash | $188112 | $290284 |

---

------

**Glossary of Terms**

*LTM Calculated Billings:* We believe calculated billings on a last 12-months basis helps investors better understand our performance for a particular period given the seasonality in our model due to quarterly fluctuations based on the timing of new client launches and number of intra-year launches. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings. Our revenue generally does not reflect this seasonality and these quarterly fluctuations given that we recognize revenue ratably over the term that members have access to our platform. LTM calculated billings are defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given 12-month period.

*Clients:* We view this number as an important metric to assess the performance of our business as an increased number of clients drives growth, increases brand awareness, and helps provide scale to our business. Clients are defined as businesses or organizations, which we call entities, that have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at least one active client agreement with us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there being multiple fully-insured employers within that entity that have access to our platform.

**Non-GAAP Financial Measures**

In addition to our results prepared in accordance with GAAP, we believe the following non-GAAP financial measures, including non-GAAP gross profit and gross margin, non-GAAP income from operations and operating margin, non-GAAP operating expenses, non-GAAP net income attributable to common stockholders, diluted, non-GAAP net income per share attributable to common stockholders, diluted (which we refer to as "non-GAAP diluted net income per share") and free cash flow and free cash flow margin included in this press release, provide users of our financial information with additional useful information in evaluating our performance and liquidity and allows them to more readily compare our results across periods without the effect of non-cash and other items as detailed below. Additionally, our management and board of directors use our non-GAAP financial measures to evaluate our performance and liquidity, identify trends and make strategic decisions.

There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our non-GAAP financial measures should not be considered in isolation or as alternatives to gross profit, gross margin, income from operations, net income attributable to common stockholders, net income per share attributable to common stockholders, net cash provided by (used in) operating activities or any other measure of financial performance calculated and presented in accordance with GAAP.

***Non-GAAP Gross Profit and Gross Margin***

We define non-GAAP gross profit as gross profit presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation**,** and amortization of intangible assets. We define non-GAAP gross margin as non-GAAP gross profit divided by revenue.

The principal limitation of non-GAAP gross profit and non-GAAP gross margin is that they exclude significant expenses that are required by GAAP to be recorded in our unaudited condensed consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

***Non-GAAP Income From Operations and Operating Margin***

We define non-GAAP income from operations as income from operations presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and acquisition-related expenses. We define non-GAAP operating margin as non-GAAP income from operations divided by revenue.

------

The principal limitation of non-GAAP income from operations and non-GAAP operating margin is that they exclude significant expenses that are required by GAAP to be recorded in our unaudited condensed consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

***Non-GAAP Operating Expenses***

We define non-GAAP operating expenses as operating expenses presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and acquisition-related expenses.

The principal limitation of non-GAAP research and development expenses, non-GAAP sales and marketing expenses and non-GAAP general and administrative expenses is that they exclude significant expenses that are required by GAAP to be recorded in our unaudited condensed consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

***Non-GAAP Net Income Attributable to Common Stockholders, Diluted and Non-GAAP Net Income Per Share Attributable to Common Stockholders, Diluted***

We define non-GAAP net income attributable to common stockholders, diluted and non-GAAP net income per share attributable to common stockholders, diluted (which we refer to as "non-GAAP diluted net income per share") as GAAP net income attributable to common stockholders and GAAP net income per share attributable to common stockholders, diluted, respectively, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation, employer payroll taxes related to stock-based compensation, amortization of intangible assets, acquisition-related expenses and the income tax effects related to non-GAAP adjustments.

***Free Cash Flow and Free Cash Flow Margin***

We define free cash flow as net cash provided by (used in) operating activities plus cash used for employer payroll taxes at IPO related to stock-based compensation less purchases of property, equipment and software (including capitalized internal-use software). We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or used by our operations that, after taking into account the employer payroll taxes paid as part of the vesting of shares at IPO as well as investments in property, equipment and software (including capitalized internal-use software), can be used for strategic initiatives, including investing in our business and strengthening our financial position. The principal limitation of free cash flow is that it does not represent the total increase or decrease in our cash balance for a given period. We define free cash flow margin as free cash flow divided by revenue.

We adjust the following items from one or more of our non-GAAP financial measures:

***Stock-based compensation expense.*** We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding our operating performance.

***Employer payroll tax expense related to stock-based compensation.*** We exclude expenses for employer payroll taxes related to stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, this expense is tied to the exercise, vesting or sale of underlying equity awards and the price of our common stock at the time of exercise, vesting or sale which may vary from period to period independent of the operating performance of our business.

***Amortization of intangible assets.*** We exclude amortization of intangible assets, which is a non-cash expense, from certain of our non-GAAP financial measures. Our expenses for amortization of intangible assets are inconsistent in amount and frequency because they are significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. We exclude these amortization expenses because we do not believe these expenses have a direct correlation to the operating performance of our business.

***Acquisition-related expenses.*** We exclude certain charges that are attributable to acquiring businesses. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

------

***Income tax effect of non-GAAP adjustments.*** We exclude the valuation allowance that is attributable to our non-GAAP income beginning in 2025. For the quarter ended March 31, 2026 we used a forecasted annual tax rate of 24% and for the quarter ended March 31, 2025 we used an annual tax rate of 20%. These tax rates reflect current available information, as well as other factors and assumptions. We will periodically re-evaluate this tax rate, as necessary, for significant events, relevant tax law changes, material changes in the forecasted geographic earnings mix, and any significant transactions.

------

 **HINGE HEALTH, INC.**

**(unaudited)**

**(in thousands, except percentages)**

**Reconciliation of GAAP to Non-GAAP Financial Measures:**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP gross profit | $154233 | $100233 |
| *GAAP gross margin* | *85 %* | *81 %* |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | 837 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | 105 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 225 | 181 |
| Non-GAAP gross profit | $155400 | $100414 |
| *Non-GAAP gross margin* | *85 %* | *81 %* |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP income from operations | $32069 | $13137 |
| *GAAP operating margin* | *18 %* | *11 %* |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | 11692 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | 1484 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 225 | 181 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expenses | 694 | 1631 |
| Non-GAAP income from operations | $46164 | $14956 |
| *Non-GAAP operating margin* | *25 %* | *12 %* |

---

(1)Stock-based compensation expense:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Cost of revenue | $837 | $— |
| Research and development | 3433 |  |
| Sales and marketing | 4004 |  |
| General and administrative | 3418 | 7 |
| Total stock-based compensation expense | $11692 | $7 |

---

------

**HINGE HEALTH, INC.**

**(unaudited)**

**(in thousands, except per share amounts)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP net income attributable to common stockholders, diluted | $34061 | $121313 |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | 11692 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | 1484 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 225 | 181 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expenses | 694 | 1631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax effect of non-GAAP adjustments | (11196) | (2992) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other dilutive | (88) |  |
| Non-GAAP net income attributable to common stockholders, diluted | $36872 | $120140 |
| Non-GAAP net income attributable to common stockholders per share, diluted | $0.45 | $1.30 |
| Weighted average shares used in computing non-GAAP net income per share attributable to common stockholders, diluted | 82394 | 92746 |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP net income per share attributable to common stockholders, diluted | $0.41 | $1.31 |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | 0.14 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | 0.02 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 0.01 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expenses | 0.01 | 0.02 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax effect of non-GAAP adjustments | (0.14) | (0.03) |
| Non-GAAP net income per share attributable to common stockholders, diluted | $0.45 | $1.30 |

---

(1)For details on stock-based compensation expense, see above.

(2)Some columns may not add due to rounding.

------

**HINGE HEALTH, INC.**

**(unaudited)**

**(in thousands, except for percentages)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP research and development | $30338 | $23499 |
| *GAAP research and development as a percentage of revenue* | *17 %* | *19 %* |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | (3433) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | (672) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expenses | (694) | (1458) |
| Non-GAAP research and development | $25539 | $22041 |
| *Non-GAAP research and development as a percentage of revenue* | *14 %* | *18 %* |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP sales and marketing | $68802 | $46716 |
| *GAAP sales and marketing as a percentage of revenue* | *38 %* | *38 %* |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | (4004) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | (409) |  |
| Non-GAAP sales and marketing | $64389 | $46716 |
| *Non-GAAP sales and marketing as a percentage of revenue* | *35 %* | *38 %* |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| GAAP general and administrative | $23024 | $16881 |
| *GAAP general and administrative as a percentage of revenue* | *13 %* | *14 %* |
| Non-GAAP adjustments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense <sup>(1)</sup> | (3418) | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer payroll tax expense related to stock-based compensation | (298) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expenses |  | (174) |
| Non-GAAP general and administrative | $19308 | $16700 |
| *Non-GAAP general and administrative as a percentage of revenue* | *11 %* | *13 %* |

---

(1)For details on stock-based compensation expense, see above.

------

**HINGE HEALTH, INC.**

**(unaudited)**

**(in thousands, except for percentages)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net cash provided by operating activities | $43083 | $4925 |
| *Operating cash flow margin* | *24 %* | *4 %* |
| Less purchases of property, equipment and software (including capitalized internal use software) | (1530) | (757) |
| Free cash flow | $41553 | $4168 |
| *Free cash flow margin* | *23 %* | *3 %* |
| Net cash (used in) provided by investing activities | $48081 | $(21331) |
| Net cash (used in) provided by financing activities | $(112848) | $4104 |

---

**Investor Relations Contact:**

ir@hingehealth.com

**Media Contact:**

media@hingehealth.com